drugset / Trial / NCT02510274

Single and Multiple Dosing Study in Hemodialysis Patients With Hyperphosphatemia in Japan

NCT02510274 ↗

Phase 1 Completed 24 enrolled Astellas Pharma Inc
RandomizedParallel-groupOpen-labelTreatment

Summary

The objective of this study is to assess PK, safety and tolerability of a single oral dose of ASP3325 and to assess PD, PK and safety of repeated oral doses of ASP3325 administered t.i.d. before or just after each meal

Timeline

Start
2014-05-12
Primary completion
2014-11-04
Completion
2014-11-04

Drugs

EvaluationDrugModalityDoseRoute
Subject ASP3325 Unknown — Oral